Biogen (BIIB) Common Equity (2009 - 2026)

Biogen has reported Common Equity for 18 years, with the latest figure at $18.8 billion in Q2 2026.

• On a quarterly basis, Common Equity rose 6.88% year-over-year to $18.8 billion in Q2 2026; TTM through Jun 2026 was $18.8 billion, a 6.88% increase from a year earlier, with the FY2025 full-year figure at $18.3 billion, up 9.22% from the prior year.
• Common Equity was $18.8 billion for Q2 2026 at Biogen, up from $18.7 billion in the prior quarter.
• The five-year high for Common Equity was $18.8 billion in Q2 2026, with the low at $11.2 billion in Q1 2022.
• Average Common Equity over 5 years is $15.5 billion, with a median of $15.6 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Common Equity rose 5.23% in 2022, then grew 22.87% in 2023.
• Over 5 years, Common Equity stood at $13.4 billion in 2022, then rose by 10.54% to $14.8 billion in 2023, then increased by 12.95% to $16.7 billion in 2024, then gained by 9.22% to $18.3 billion in 2025, then increased by 3.24% to $18.8 billion in 2026.
• The last three Common Equity figures came in at $18.8 billion (Q2 2026), $18.7 billion (Q1 2026), and $18.3 billion (Q4 2025), per Business Quant data.